These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9192757)

  • 21. The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S.
    Egan JO; Kalafatis M; Mann KG
    Protein Sci; 1997 Sep; 6(9):2016-27. PubMed ID: 9300501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood coagulation factor Va abnormality associated with resistance to activated protein C in venous thrombophilia.
    Sun X; Evatt B; Griffin JH
    Blood; 1994 Jun; 83(11):3120-5. PubMed ID: 8193349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glycosylation of bombesin receptors: characterization, effect on binding, and G-protein coupling.
    Kusui T; Benya RV; Battey JF; Jensen RT
    Biochemistry; 1994 Nov; 33(44):12968-80. PubMed ID: 7947701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Resistance to activated protein C due to mutated factor V as a novel cause of inherited thrombophilia.
    De Stefano V; Leone G
    Haematologica; 1995; 80(4):344-56. PubMed ID: 7590506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma factor V activation is prevented by activated protein C in the presence of phospholipid vesicles, not platelets.
    Solymoss S; Nguyen KT
    Thromb Haemost; 1993 Feb; 69(2):124-9. PubMed ID: 8456424
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel exosite in the light chain of human activated protein C essential for interaction with blood coagulation factor Va.
    Mesters RM; Heeb MJ; Griffin JH
    Biochemistry; 1993 Nov; 32(47):12656-63. PubMed ID: 8251484
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanisms that regulate the anticoagulant function of coagulation factor V.
    Thorelli E
    Scand J Clin Lab Invest Suppl; 1999; 229():19-26. PubMed ID: 10097286
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A prothrombinase-based assay for detection of resistance to activated protein C.
    Nicolaes GA; Thomassen MC; van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
    Thromb Haemost; 1996 Sep; 76(3):404-10. PubMed ID: 8883278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The activities of recombinant gamma-carboxyglutamic-acid-deficient mutants of activated human protein C toward human coagulation factor Va and factor VIII in purified systems and in plasma.
    Jhingan A; Zhang L; Christiansen WT; Castellino FJ
    Biochemistry; 1994 Feb; 33(7):1869-75. PubMed ID: 8110790
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding.
    Camire RM; Kalafatis M; Tracy PB
    Biochemistry; 1998 Aug; 37(34):11896-906. PubMed ID: 9718313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the molecular defect in factor VR506Q.
    Kalafatis M; Bertina RM; Rand MD; Mann KG
    J Biol Chem; 1995 Feb; 270(8):4053-7. PubMed ID: 7876154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. beta 2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface.
    Mori T; Takeya H; Nishioka J; Gabazza EC; Suzuki K
    Thromb Haemost; 1996 Jan; 75(1):49-55. PubMed ID: 8713779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. APC-resistance as measured by a Textarin time assay: comparison to the APTT-based method.
    Hoagland LE; Triplett DA; Peng F; Barna L
    Thromb Res; 1996 Sep; 83(5):363-73. PubMed ID: 8873345
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
    Montes MA; Fox EA; Longtine JA; Dorfman DM
    Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mechanism of inactivation of human platelet factor Va from normal and activated protein C-resistant individuals.
    Camire RM; Kalafatis M; Cushman M; Tracy RP; Mann KG; Tracy PB
    J Biol Chem; 1995 Sep; 270(35):20794-800. PubMed ID: 7657663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Investigation of genotype-dependent differences in factor V activity as well as response to activated protein C by application of different methods.
    Siegert G; Kostka H; Kuhlisch E; Schwarz T; Schellong SM; Jaross W
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):683-90. PubMed ID: 11734669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of hyperhomocysteinemia on protein C activation and activity.
    Lentz SR; Piegors DJ; Fernández JA; Erger RA; Arning E; Malinow MR; Griffin JH; Bottiglieri T; Haynes WG; Heistad DD
    Blood; 2002 Sep; 100(6):2108-12. PubMed ID: 12200374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Gla26 residue of protein C is required for the binding of protein C to thrombomodulin and endothelial cell protein C receptor, but not to protein S and factor Va.
    Nishioka J; Ido M; Hayashi T; Suzuki K
    Thromb Haemost; 1996 Feb; 75(2):275-82. PubMed ID: 8815576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V.
    Heeb MJ; Kojima Y; Greengard JS; Griffin JH
    Blood; 1995 Jun; 85(12):3405-11. PubMed ID: 7780127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Peptidomimetic inhibitors for activated protein C: implications for hemophilia management.
    Butenas S; Orfeo T; Kalafatis M; Mann KG
    J Thromb Haemost; 2006 Nov; 4(11):2411-6. PubMed ID: 17059471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.